Payment overview · 2025
General Payments
$1,842.66
95 reported records · 9 companies
Healthcare provider profile · identity verified
Saurabh Sharma, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PATTERSON, CA · NPI 1629136478
Verified facts
What the public records show
CMS Open Payments records show Saurabh Sharma, D.O. received $1,842.66 in general payments during 2025 across 95 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $406.45 | 22.1% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $308.63 | 16.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $300.10 | 16.3% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $236.43 | 12.8% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $180.80 | 9.8% | 17 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $161.61 | 8.8% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.41 | 5.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.35 | 4.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.88 | 3.2% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,842.66 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $236.43 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $180.80 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $180.80 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $173.20 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.32 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $161.61 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $158.58 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $153.83 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $153.81 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.05 | 7 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $141.21 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $130.58 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $113.32 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $103.41 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.72 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $85.35 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.88 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.25 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 410 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 47 |
| Losartan Potassium | Losartan Potassium | 198 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 44 |
| Metformin Hcl | Metformin Hcl | 171 | 43 |
| Furosemide | Furosemide | 153 | 49 |
| Omeprazole | Omeprazole | 146 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 34 |
| Trazodone Hcl | Trazodone Hcl | 130 | 34 |
| Lisinopril | Lisinopril | 119 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 62 |
| Gabapentin | Gabapentin | 117 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 34 |
| Bupropion Xl | Bupropion Hcl | 100 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 30 |
| Mounjaro | Tirzepatide | 92 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 21 |
| Prednisone | Prednisone | 88 | 37 |
| Alprazolam | Alprazolam | 83 | 24 |
| Tramadol Hcl | Tramadol Hcl | 80 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 39 |
| Meloxicam | Meloxicam | 77 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 17 |
| Metformin Hcl Er | Metformin Hcl | 67 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 16 |
| Ozempic | Semaglutide | 50 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Allopurinol | Allopurinol | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 15 |
| Azithromycin | Azithromycin | 40 | 24 |
| Spironolactone | Spironolactone | 39 | 11 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Eliquis | Apixaban | 30 | 11 |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Hydrocortisone | Hydrocortisone | 24 | 17 |
| Nystatin | Nystatin | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 15 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 14 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Lactulose | Lactulose | 21 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Colchicine | Colchicine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,842.66 · 95 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TEZSPIRE, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error